IP Library › Granted Patent US 12,642,760
Granted Patent B2
US 12,642,760 · App. 17/635,011 · Granted Jun 2, 2026

Implantable capsule

Inventors: Aurélien Lathuilière (Geneva, CH); Julien Grogg (Lausanne, CH); Nicolas Mach (Collonge-Bellerive, CH)
Assignees: RELEASE THERAPEUTICS SA; LES HOPITAUX UNIVERSITAIRES DE GENEVE; UNIVERSITE DE GENEVE GENEVE
A61K9/0024A61K35/34A61K38/193A61L27/26A61L27/3826A61L2300/62
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,642,760
App. No.
17/635,011
Granted
Jun 2, 2026
Kind
B2
Abstract

Implantable capsule comprising a cell receiving portion ( 2 ) comprising a porous membrane ( 5 ) surrounding a cell receiving chamber ( 13 ) for receiving immortalized cells in a liquid media therein for the secretion of therapeutic agents. The capsule further comprises a cell support matrix ( 7 ) inserted within the cell receiving chamber ( 13 ) configured for the arrangement of the immortalized cells within the cell receiving chamber.

Claims (20)

1 . An implantable capsule comprising a cell receiving portion comprising:

(a) a porous membrane surrounding a cell receiving chamber for receiving genetically engineered immortalized cells in a liquid media therein for the secretion of therapeutic agents, and

(b) a membrane support mounted in the cell receiving chamber configured for providing structural support to the porous membrane, the membrane support comprising a coil made of a biocompatible material,

wherein the capsule further comprises a cell support matrix comprising at least one yarn inserted within the cell receiving chamber configured for the arrangement of the immortalized cells within the cell receiving chamber, said coil surrounding said at least one yarn.

2 . The implantable capsule according to claim 1 , wherein said at least one yarn comprises a polyester material.

3 . The implantable capsule according to claim 1 , wherein the cell support matrix comprises a plurality of said yarns.

4 . The implantable capsule according to claim 3 , wherein the plurality of yarns is in a range of 5 to 20 yarns.

5 . The implantable capsule according to claim 3 , wherein the plurality of yarns is in a range of 5 to 15 yarns.

6 . The implantable capsule according claim 1 , wherein the at least one yarn extends within the cell receiving chamber over at least 80% of a length of the cell receiving chamber.

7 . The implantable capsule according to claim 1 further comprising an extractor portion coupled to an extractor end of the cell receiving portion configured for allowing a surgical tool to pull the implantable capsule out of an implantation site, the extractor portion comprising a retrieval thread.

8 . The implantable capsule according to claim 7 , wherein the retrieval thread is made of a thread of polypropylene.

9 . The implantable capsule according to claim 7 , wherein the extractor portion comprises an anchor tube having a cavity therein within which an anchor portion of a retrieval thread is inserted and bonded.

10 . The implantable capsule according to claim 9 , wherein the anchor tube consists of or comprises a polyurethane material.

11 . The implantable capsule according to claim 9 , wherein the extractor portion is coupled to the cell receiving portion via a coupling comprising a connector, a connector comprising a portion inserted into an extractor end of the porous membrane and second portion inserted in a coupling end of the anchor tube.

12 . The implantable capsule according to claim 11 , wherein the connector is bonded to the anchor tube and the cell receiving portion by an adhesive.

13 . The implantable capsule according to claim 12 , wherein the adhesive is a light curable adhesive.

14 . The implantable capsule according to claim 1 , wherein an outer diameter of the capsule is in a range of 0.5 to 3 millimeters and has a length in a range of 5 to 25 millimeters.

15 . The implantable capsule according to claim 1 , wherein a length to diameter ratio of the capsule is in a range of 5 to 20.

16 . The implantable capsule according to claim 14 , wherein the capsule has an outer diameter in a range of 0.8 to 1.5 millimeters.

17 . The implantable capsule according to claim 14 , wherein the capsule has a length in a range of 8 to 20 millimeters.

Assignments (2)
CHANGE OF NAME Recorded Dec 1, 2023
From: MAXIVAX SA
To: RELEASE THERAPEUTICS SA
Reel/Frame 065745/0740 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 14, 2022
From: LATHUILIÈRE, AURÉLIEN; GROGG, JULIEN; MACH, NICOLAS
To: MAXIVAX SA; LES HOPITAUX UNIVERSITAIRES DE GENEVE; UNIVERSITE DE GENEVE
Reel/Frame 058999/0585 →
Priority Claims (1)
EP 19191868 · Aug 14, 2019 · regional
Continuity (1)
Related Publication 20220287959A1 · Sep 15, 2022
References Cited (24)
US 6303136B1 · Li et al. · 2001 [cited by applicant]
US 8892217B2 · Camps et al. · 2014 [cited by applicant]
US 20220265727A1 · Lathuilière et al. · 2022 [cited by applicant]
CN 104640579 · 2015 [cited by applicant]
JP 2018515582 · 2018 [cited by applicant]
RU 2201765 · 2003 [cited by applicant]
WO WO9715195 · 1997 [cited by applicant]
WO WO0143696 · 2001 [cited by applicant]
WO WO2012075184 · 2012 [cited by applicant]
WO WO2013181424 · 2013 [cited by applicant]
WO WO2014173441 · 2014 [cited by applicant]
WO WO2016191645 · 2016 [cited by applicant]
WO 2017064571A1 · 2017 [cited by examiner]
WO WO2017064571 · 2017 [cited by applicant]
WO WO2021028500 · 2021 [cited by applicant]
Grogg, J. et al. “Engineering a versatile and retrievable cell microencapsulation device for the delivery of therapeutic proteins” [cited by applicant]
Farina, M. et al. “Cell encapsulation: Overcoming barriers in cell transplantation in diabetes and beyond” [cited by applicant]
Lathuilière, A. et al. “A high-capacity cell macroencapsulation system supporting the long-term survival of genetically engineered allogeneic cells” [cited by applicant]
Lathuilière, A. et al. “Encapsulated Cellular Implants for Recombinant Protein Delivery and Therapeutic Modulation of the Immune System” [cited by applicant]
Mach, N. et al. “Cell-based immunotherapy combining encapsulation cell technology and irradiated autologous tumor cells: A novel technology platform that is both safe and feasible. Results from first in man trial” [cited by applicant]
Salmon, P. “Generation of Human Cell Lines Using Lentiviral-Mediated Genetic Engineering” [cited by applicant]
Schwenter, F. et al. “Cell encapsulation technology as a novel strategy for human anti-tumor immunotherapy” [cited by applicant]
Townsend-Nicholson, A. et al. “Cell Electrospinning: a Unique Biotechnique for Encapsulating Living Organisms for Generating Active Biological Microthreads/Scaffolds” [cited by applicant]
Written Opinion in International Application No. PCT/EP2020/072673, Oct. 15, 2020, pp. 1-14. [cited by applicant]